Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.14 USD | +2.19% | -3.24% | +7.67% |
May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
Financials (USD)
Sales 2024 * | 583M | Sales 2025 * | 597M | Capitalization | 1.08B |
---|---|---|---|---|---|
Net income 2024 * | 121M | Net income 2025 * | 148M | EV / Sales 2024 * | 2.11 x |
Net Debt 2024 * | 146M | Net cash position 2025 * | 194M | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
8.87
x | Employees | 197 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.55% |
Latest transcript on Collegium Pharmaceutical, Inc.
1 day | +2.19% | ||
1 week | -3.24% | ||
1 month | -10.26% | ||
3 months | -9.72% | ||
6 months | +29.30% | ||
Current year | +7.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 01-12-31 | |
Colleen Tupper
DFI | Director of Finance/CFO | 48 | 21-05-23 |
Scott Sudduth
CTO | Chief Tech/Sci/R&D Officer | - | 18-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 14-12-31 |
Gino Santini
BRD | Director/Board Member | 67 | 12-07-23 |
John Freund
BRD | Director/Board Member | 70 | 14-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.25% | 28 M€ | -1.00% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 33.14 | +2.19% | 566,503 |
24-05-30 | 32.43 | -2.32% | 877,216 |
24-05-29 | 33.2 | -3.40% | 417,544 |
24-05-28 | 34.37 | +0.35% | 352,441 |
24-05-24 | 34.25 | +1.27% | 320,990 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.67% | 1.08B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- COLL Stock